Advertisement

Topics

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma

07:30 EDT 19 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- Company Plans to Initiate Multi-center, Phase 1 Trial in Second Half of 2017 - - ACTR707 is Optimized for Development in Both Hematologic and Solid Tumors - Unum Therapeutics, a clinical stage biopha...

Other Sources for this Article

Unum Therapeutics Inc.
Jeff Michaels, +1-617-843-3820
Corporate_Communications@unumrx.com

NEXT ARTICLE

More From BioPortfolio on "Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...